Mardil Selen® (Mardil Selen)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspsolution for external use
Composition:

Active substance: Mardil Selenium substance-solution (0.9% solution of selenious acid in 90% 2,2-dichloropropionic acid) 0.78 g Excipient-. purified water 0.22 g

Description:

transparent colorless or light yellow liquid with a specific odor. A light precipitate is allowed.

Pharmacotherapeutic group:Local necrotizing agent
ATX: & nbsp
  • Other preparations for the treatment of skin diseases
    • Pharmacodynamics:

    Mardil Selen® is a solution of selenious acid (0.45% in terms of selenium) in 70% 2,2-dichloropropionic acid. When applied externally to affected areas of the skin, the drug is capable of interrupting the growth and vital activity of pathologically altered cells, including benign new skin and malignant nonmetastatic skin tumors through angiocoagulation, dehydration and devitalization. The effect of the drug on the affected area of ​​the skin provides a direct intravital fixation followed by mummification of the pathologically altered tissue with which the drug comes into contact. The immediate effect of the drug is expressed in the appearance of a characteristic whitish-gray or grayish color. Devitalized after the effect of the drug, the tissue is dehydrated and, as it mummifies, becomes dark brown in color.The formed mummified scab exfoliates after complete re-epithelization, after 2-4 weeks. The healing proceeds without complications, especially in the absence of secondary infection, leaving no significant scars and scars, deformations of adjacent tissues or organ function disorders.

    Pharmacokinetics:

    When Mardil Selen® was applied to the affected areas of the skin, absorption of active substances and their systemic effect on the body were not detected.

    Indications:

    Mardil Selen® is intended for external treatment of benign skin lesions (low-pigment and unpigmented nevi, papillomatous nevi, skin horn, seborrheic keratosis and other keratoses), vascular benign neoplasms (senile hemangioma, angiokeratoma, angiomatous nevus), benign skin formations of viral origin (common warts , plantar warts, flat warts, papillomas), non-metastasizing malignant skin tumors (basal cell carcinoma of 1 st).

    Contraindications:

    Hypersensitivity to the components of the drug, malignant skin tumors prone to metastasis,marked propensity to form keloids, age to 18 years, pregnancy, lactation.

    Dosing and Administration:

    Outwardly

    Treatment of basal cell carcinoma. Treatment is carried out on an outpatient basis, under the supervision of a doctor. The procedure does not require anesthesia. The preparation is applied with a thin wooden spatula or with the help of the attached glass capillary to the previously degreased 70% alcohol surface of the formation. The treatment is carried out by several applications at intervals of 1-2 minutes, taking 1-2 mm of apparently healthy skin, until a dense whitish-gray coloration appears. Change in color of the tissue occurs within 2-3 minutes after application of the drug. At the same time, the consistency of the neoplasm changes to a more dense one. The dose of the drug depends on the stage, clinical form and density of the tumor and can be up to 0.2 ml. The maximum daily dose of 0.2 ml.

    The standard course of therapy for basal cell cancer in Stage 1 includes a 3-fold treatment of the tumor and is performed on days 1, 2 or 3 and on days 8 or 9. Additional, 4 applications of Mardil Selen® are allowed after rejection of a mummified scab at the doctor's discretion.Around the neoplasm after application of the drug Mardil Selen®, a transient band of hyperemia and edema is observed, which passes 24-48 hours after the completion of the procedure. Any additional medical measures after the application of the drug is not required. The next day after the application, the pathological focus is mummified, acquires a dark brown hue and sharply decreases in size. Mummified scab is separated only after complete epithelization spontaneously after 2-4 weeks. The healing takes place without complications, especially in the absence of secondary infection, leaving no significant scarring, scars and deformities of adjacent tissues or impaired functions of the organs.

    Treatment of benign skin tumors, vascular benign neoplasms of the skin, benign skin formations of viral origin. Treatment is carried out on an outpatient basis under the supervision of a physician. The standard procedure is performed once and does not require anesthesia. The preparation is applied with a thin wooden spatula or with the help of the attached glass capillary to the previously degreased 70% alcohol surface of the formation.The treatment is carried out by several applications at intervals of 1 -2 minutes before the appearance of whitish-gray or grayish staining. Change in color of the tissue occurs within 2-3 minutes after application of the drug, in the presence of severe hyperkeratosis - within 5-7 minutes. At the same time, the consistency of the neoplasm changes to a more dense one. The dose of the drug depends on the type, size, density and severity of hyperkeratosis and can range from 0.02 ml to 0.2 ml. The maximum daily dose of 0.2 ml.

    Around the neoplasm after application of the drug Mardil Selen®, a transient band of hyperemia and edema is observed, which disappears without a trace 24-48 hours after the completion of the procedure. Any additional medical measures after the application of the drug is not required. The next day after the application, the pathological focus is mummified, acquires a dark brown hue and sharply decreases in size. Mummified scabs are separated only after complete epithelization spontaneously after 2-3 weeks. The healing proceeds without complications, especially in the absence of secondary infection, leaving no significantscars and deformities of adjacent tissues or disorders of organ functions.

    In large neoplasms and tumors with severe hyperkeratosis, in case of their incomplete removal, it is possible to apply the drug again.

    Side effects:

    The use of Mardil Selen® can lead to a change in skin pigmentation and the formation of superficial cicatricial changes. With the normal course of the process of epithelialization, the absence of secondary infection and the independent separation of mummified scabs, the probability of such consequences is small. There may be swelling of the tissue, very rarely with individual sensitivity to the components of the drug, allergic reactions in the form of pruritus are possible.

    Overdose:

    If Mardil Selen® is used incorrectly to prevent damage to deeper layers of the skin, the preparation should be rinsed with running water. Healing can occur independently without the use of additional drugs or with the use of wound healing drugs.

    Interaction:

    The interaction of the drug Mardil Selen® with other drugs of external action is not established.

    Special instructions:

    Handle with care.

    Before opening the vial should be shaken and move the solution, which got in the top of the bottle, to its bottom. The opened vial should be in a strictly vertical position.

    Mardil Selen® contains an acid in its composition. Avoid getting the product on healthy skin or mucous membranes. If an accidental ingestion of Mardil Selen® to a healthy skin or mucous membrane occurs, remove the drug as soon as possible with a cotton swab moistened with water. In the treatment of affected skin areas located near the eye area, special precautions should be observed. Avoid getting into the eyes! If an accidental ingestion of Mardil Selen® in the eye occurs, rinse immediately with plenty of water and 1% sodium hydrogen carbonate solution, and then consult a doctor.

    It is impossible to remove the mummified scab by scraping or using mechanical means. The scab should separate from the healthy skin by itself, otherwise it may damage the processes of tissue healing and the formation of scars.Until complete healing of the skin is not recommended to swim in swimming pools and open water, and should avoid exposure to direct sunlight and ultraviolet radiation. On the day of treatment it is recommended to limit water procedures. It is advisable to avoid traumatization and contamination of the treated pathological focus until complete epithelialization.

    Disposal of used vials: before discarding the vial, the rests of the drug should be washed off in running water. Empty vial can be thrown into the garbage container.

    Form release / dosage:

    Solution for external use.


    Packaging:

    By 0.5 or 1 ml of solution in the fl owcon of light-protective glass, ukuporous rubber cover with by rolling combined aluminumplastic cap.

    One bottle with a set of glass microcapillaries (5 pieces) are placed in a plastic pallet or cardboardand with the instructionapplication in cardboard pack.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:3 years. Do not use the medicinal product after the expiration date indicated on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-000528
    Date of registration:12.05.2011 / 24.03.2015
    Expiration Date:12.05.2016
    The owner of the registration certificate:OXYGON, LTD. OXYGON, LTD. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp03.02.2016
    Illustrated instructions
      Instructions
      Up